Next, we evaluated the clinical relevance of RET as a biomarker of response/resistance to combined CDK4/6i and endocrine therapy in a cohort of ER+ advanced breast cancer patients that has been previously described (37, 48). The gene discussed is ESR1; the disease is breast carcinoma.